Human immunodeficiency virus testing practices among buprenorphine- prescribing physicians

Journal of Addiction Medicine

Volumn 6, Issue 2, 2012, Pages 159-165

  Edelman, E Jennifer ^a,b,c,d   Dinh, An T ^b   Moore, Brent A ^b   Schottenfeld, Richard S ^b,c   Fiellin, David A ^b,c   Sullivan, Lynn E ^b,c  

^a ROBERT WOOD JOHNSON FOUNDATION   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Buprenorphine; Cross sectional study; HIV screening; Physicians

Indexed keywords

BUPRENORPHINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CIGARETTE SMOKING; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOCTOR PATIENT RELATION; DRUG DEPENDENCE; FEMALE; HIGH RISK POPULATION; HIV TEST; HUMAN; MALE; MEDICAL EXAMINATION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SCREENING; SEXUAL BEHAVIOR; SPECIALIZATION;

ADOLESCENT; ADULT; AIDS SERODIAGNOSIS; BUPRENORPHINE; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RISK-TAKING; UNITED STATES; UTILIZATION REVIEW; YOUNG ADULT;

EID: 84863684956     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31824339fc     Document Type: Article

References (43)

1. Abraham AJ, O'Brien LA, Bride BE, Roman PM. HIV/AIDS services in private substance abuse treatment programs. Drug Alcohol Depend 2011;115(1/2):16-22.
2. Alford DP, La Belle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011;171(5):425-431.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000.
4. Bokhour BG, Solomon JL, Knapp H, et al. Barriers and facilitators to routine HIV testing in VA primary care. J Gen Intern Med 2009;24(10):1109-1114.
5. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR-14):1-17; quiz CE11-14.
6. Brown LS Jr, Kritz S, Goldsmith RJ, et al. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep 2007;122(4):441-451.
7. Brown LS, Kritz S, Muhammad A, et al. Disparities in health services for HIV/AIDS, hepatitis C virus, and sexually transmitted infections: role of substance abuse treatment programs. J Addict Med 2009;3(2):95-102.
8. Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don't physicians test for HIV? A review of the US literature. AIDS 2007;21(12):1617-1624.
9. Campsmith ML, Rhodes PH, Hall HI, et al. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr 2010;53(5):619-624.
10. Chun TH, Spirito A, Rakowski W, et al. Beliefs and practices of pediatric emergency physicians and nurses regarding counseling alcohol-using adolescents: can counseling practice be predicted? Pediatr Emerg Care 2011;27(9):812-825.
11. Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Me d 2008;40(7):500-506.
12. Des Jarlais DC, Arasteh K, Perlis T, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007;21(2):231-235.
13. Dookeran NM, Burgess JF Jr, Bowman CC, et al. HIV screening among substance-abusing veterans in care. J Subst Abuse Treat 2009;37(3):286-291.
14. Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med 2010;25(9):936-941.
15. Gongidi P, Sierakowski JJ, Bowen GS, et al. Survey of attitudes and practices of osteopathic primary care physicians regarding taking of sexual histories and HIV screening. J Am Osteopath Assoc 2010;110(12):712-720.
16. Greene P. Outpatient Drug Utilization Trends for Buprenorphine Years 2002-2009. Available at: http://buprenorphine.samhsa.gov/bwns/2010- presentations-pdf/09-Greene-508.pdf. Accessed September 20, 2011.
17. Gyarmathy VA, Neaigus A, Miller M, et al. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr 2002;30(4):448-456.
18. Institute of Medicine. No Time to Lose: Making the Most of HIV Prevention. Washington, DC: Institute of Medicine; 2000.
19. Jenkins TC, Gardner EM, Thrun MW, et al. Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care Settings. Sex Transm Dis 2006;33(5):329-333.
20. Katz MA, Lamias MJ, Shay DK, et al. Use of rapid tests and antiviral medications for influenza among primary care providers in the United States. Influenza Other Respi Viruses 2009;3(1):29-35.
21. Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010;19(6):557-568.
22. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006;20(10):1447-1450.
23. Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007;22(4):527-530.
24. Neaigus A, Miller M, Friedman SR, et al. Sexual transmission risk among noninjecting heroin users infected with human immunodeficiency virus or hepatitis C virus. J Infect Dis 2001;184(3):359-363.
25. + cell strata. Ann Intern Med 2003;138(8):620-626.
26. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of officebased buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010;106(1):56-60.
27. Pollack HA, D'Aunno T. HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005. J Subst Abuse Treat 2010;38(4):307-316.
28. Schwartz JS, Lewis CE, Clancy C, et al. Internists' practices in health promotion and disease prevention. A survey. Ann Intern Med 1991;114(1):46-53.
29. Shirts BH, Perera S, Hanlon JT, et al. Provider management of and satisfaction with laboratory testing in the nursing home setting: results of a national Internet-based survey. J Am Med Dir Assoc 2009;10(3):161-166.e3.
30. Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009;37(4):426-430.
31. St Lawrence JS, Montano DE, Kasprzyk D, et al. STD screening, testing, case reporting, and clinical and partner notification practices: a national survey of US physicians. Am J Public Health 2002;92(11):1784-1788.
32. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med 2005;20(11):1038-1041.
33. Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health 2003;80(4) (suppl 3):iii7-iii14.
34. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and noninjecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep 2010;7(2):99-106.
35. Substance Abuse & Mental Health Services Administration, Office of Applied Studies. Results From the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings). Rockville, MD: Substance Abuse & Mental Health Services Administration; 2010a.
36. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The N-SSATS Report: Infectious Disease Screening. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010b.
37. Sullivan LE, Chawarski M, O'Connor PG, et al. The practice of officebased buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1):113-116.
38. Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioiddependent patients in office practice. Ann Intern Med 2008;148(9):662-670.
39. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008;35(1):87-92.
40. Tracy K, Brown LS, Kritz S, et al. Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis 2009;28(1):8-12.
41. Volkow ND, Montaner J. Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA 2010;303(14):1423-1424.
42. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med 2008;23(9):1393-1398.
43. Ward J, Sanson-Fisher R. Prevalence and detection of HIV risk behavior in primary care: implications for clinical preventive services. Am J Prev Med 1995;11(4):224-230.